Improving delivery and efficacy of nanomedicines in solid tumors: Role of tumor priming

Nanomedicine

Volumn 6, Issue 9, 2011, Pages 1605-1620

  Wang, Jie ^a   Lu, Ze ^a   Gao, Yue ^a   Wientjes, M Guillaume ^a   Au, Jessie L S ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

apoptosis; extracellular matrix; interstitial fluid pressure; nanomedicine; nanotechnology; paclitaxel; RNAi; tumor priming; tumor penetrating microparticles; vasculature normalization

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; GLYCERYL TRINITRATE; MONOCLONAL ANTIBODY DC101; NANOCARRIER; NAVELBINE; PACLITAXEL; PAZOPANIB; RAZOXANE; TRASTUZUMAB;

APOPTOSIS; BREAST CANCER; DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG SELECTIVITY; EXTRACELLULAR MATRIX; HEAD AND NECK CANCER; HUMAN; INTERSTITIAL FLUID; LUNG CANCER; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SOLID TUMOR; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; NANOMEDICINE; NEOPLASMS; PACLITAXEL;

EID: 81255143243     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.11.141     Document Type: Review

References (98)

1. Kim BY, Rutka JT, Chan WC. Nanomedicine. N. Engl. J. Med. 363(25), 2434-2443 (2010).
2. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J. 19(3), 311-330 (2005).
3. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 5(3), 161-171 (2005).
4. Ibrahim NK, Desai N, Legha S et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. 8(5), 1038-1044 (2002).
5. Zhang JA, Xuan T, Parmar M et al. Development and characterization of a novel liposome-based formulation of SN-38. Int. J. Pharm. 270(1-2), 93-107 (2004).
6. Kim JH, Kim YS, Park K et al. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J. Control. Release 127(1), 41-49 (2008).
7. Tuscano JM, Martin SM, Ma Y, Zamboni W, O'Donnell RT. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted PEGylated liposomal doxorubicin in a β-cell non- Hodgkin's lymphoma xenograft mouse model. Clin. Cancer Res. 16(10), 2760-2768 (2010).
8. Chakraborty C, Sarkar B, Hsu CH, Wen ZH, Lin CS, Shieh PC. Future prospects of nanoparticles on brain targeted drug delivery. J. Neurooncol. 93(2), 285-286 (2009).
9. Ma P, Dong X, Swadley CL et al. Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia. J. Biomed. Nanotechnol. 5(2), 151-161 (2009).
10. Wang J, Lu Z, Wientjes MG, Au JL. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 12(4), 492-503 (2010).
11. Nie S. Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine (Lond.) 5(4), 523-528 (2010).
12. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7(9), 771-782 (2008).
13. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8(2), 129-138 (2009).
14. Jang SH, Wientjes MG, Lu D, Au JL. Drug delivery and transport to solid tumors. Pharm. Res. 20(9), 1337-1350 (2003).
15. Cairns R, Papandreou I, Denko N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol. Cancer Res. 4(2), 61-70 (2006).
16. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5(4), 505-515 (2008).
17. Lu D, Wientjes MG, Lu Z, Au JL. Tumor priming enhances delivery and efficacy of nanomedicines. J. Pharmacol. Exp. Ther. 322(1), 80-88 (2007).
18. Suzuki M, Hori K, Abe I, Saito S, Sato H. A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J. Natl Cancer Inst. 67, 663-669 (1981).
19. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64(11), 3731-3736 (2004).
20. Nagamitsu A, Greish K, Maeda H. Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors. Jpn J. Clin. Oncol. 39(11), 756-766 (2009).
21. Chang E, Chalikonda S, Friedl J et al. Targeting vaccinia to solid tumors with local hyperthermia. Hum.Gene Ther. 16(4), 435-444 (2005).
22. Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res. 60, 4440-4445 (2000).
23. Le Serve AW, Hellmann K. Metastases and the normalization of tumour blood vessels by ICRF 159: a new type of drug action. Br. Med. J. 1(5800), 597-601 (1972).
24. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706), 58-62 (2005).
25. Tailor TD, Hanna G, Yarmolenko PS et al. Effect of pazopanib on tumor microenvironment and liposome delivery. Mol. Cancer Ther. 9(6), 1798-1808 (2010).
26. Lin MI, Sessa WC. Antiangiogenic therapy: creating a unique "window" of opportunity. Cancer Cell 6(6), 529-531 (2004).
27. Winkler F, Kozin SV, Tong RT et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6(6), 553-563 (2004).
28. Dickson PV, Hamner JB, Sims TL et al. Bevacizumaβ-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin. Cancer Res. 13(13), 3942-3950 (2007).
29. Maeda H, Noguchi Y, Sato K, Akaike T. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn. J. Cancer Res. 85(4), 331-334 (1994).
30. Seki T, Fang J, Maeda H. Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application. Cancer Sci. 100(12), 2426-2430 (2009).
31. Yasuda H, Nakayama K, Watanabe M et al. Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma. Clin. Cancer Res. 12(22), 6748-6757 (2006).
32. Yasuda H, Yamaya M, Nakayama K et al. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J. Clin. Oncol. 24(4), 688-694 (2006).
33. Li J, Wientjes MG, Au JL. Pancreatic cancer: pathobiology, treatment options, and drug delivery. AAPS J. 12(2), 223-232 (2010).
34. Olson P, Hanahan D. Cancer. Breaching the cancer fortress. Science 324(5933), 1400-1401 (2009).
35. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 60(9), 2497-2503 (2000).
36. Choi J, Credit K, Henderson K et al. Intraperitoneal immunotherapy for metastatic ovarian carcinoma: resistance of intratumoral collagen to antibody penetration. Clin. Cancer Res. 12(6), 1906-1912 (2006).
37. Olive KP, Jacobetz MA, Davidson CJ et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324(5933), 1457-1461 (2009).
38. Tian H, Callahan CA, DuPree KJ et al. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad. Sci. USA 106(11), 4254-4259 (2009).
39. Brown E, McKee T, diTomaso E et al. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat. Med. 9(6), 796-800 (2003).
40. McKee TD, Grandi P, Mok W et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. 66(5), 2509-2513 (2006).
41. Eikenes L, Bruland OS, Brekken C, Davies CL. Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts. Cancer Res. 64(14), 4768-4773 (2004).
42. Eikenes L, Tari M, Tufto I, Bruland OS, de Lange DC. Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts. Br. J. Cancer 93(1), 81-88 (2005).
43. Stetler-Stevenson WG. Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J. Pathol. 148(5), 1345-1350 (1996).
44. Magzoub M, Jin S, Verkman AS. Enhanced macromolecule diffusion deep in tumors after enzymatic digestion of extracellular matrix collagen and its associated proteoglycan decorin. FASEB J. 22(1), 276-284 (2008).
45. Mok W, Boucher Y, Jain RK. Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus. Cancer Res. 67(22), 10664-10668 (2007).
46. Goodman TT, Olive PL, Pun SH. Increased nanoparticle penetration in collagenase-treated multicellular spheroids. Int. J. Nanomed. 2(2), 265-274 (2007).
47. Albanell J, Baselga J. Systemic therapy emergencies. Semin. Oncol 27(3), 347-361 (2000).
48. Maier U, Baumgartner G. Metaphylactic effect of mitomycin C with and without hyaluronidase after transurethral resection of bladder cancer: randomized trial. J. Urol. 141(3), 529-530 (1989).
49. Smith KJ, Skelton HG, Turiansky G, Wagner KF. Hyaluronidase enhances the therapeutic effect of vinblastine in intralesional treatment of Kaposi's sarcoma. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR).J. Am Acad. Dermatol. 36(2 Pt 1), 239-242 (1997).
50. Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clin. Cancer Res. 6(12), 4823-4830 (2000).
51. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol. 27(31), 5287-5297 (2009).
52. Kovar JL, Johnson MA, Volcheck WM, Chen J, Simpson MA. Hyaluronidase expression induces prostate tumor metastasis in an orthotopic mouse model. Am. J. Pathol. 169(4), 1415-1426 (2006).
53. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 49(16), 4373-4384 (1989).
54. Nagano S, Perentes JY, Jain RK, Boucher Y. Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. Cancer Res. 68(10), 3795-3802 (2008).
55. Kawai M, Higuchi H, Takeda M, Kobayashi Y, Ohuchi N. Dynamics of different-sized solid-state nanocrystals as tracers for a drug-delivery system in the interstitium of a human tumor xenograft. Breast Cancer Res. 11(4), R43 (2009).
56. Desai N, Trieu V, Yao Z et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 12(4), 1317-1324 (2006).
57. Desai N, Trieu V, Damascelli B, Soon-Shiong P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl. Oncol. 2(2), 59-64 (2009).
58. Von Hoff DD, Ramanathan R, Borad M et al. SPARC correlation with response to gemcitabine (G) plus naβ-paclitaxel (naβ-P) in patients with advanced metastatic pancreatic cancer: a Phase I/II study. J. Clin. Oncol. (Meeting Abstracts) 27(15S), 4525 (2009).
59. Hamilton EP, Kimmick GG, Desai N et al. Use of SPARC, EGFR, and VEGFR expression to predict response to naβ-paclitaxel (nabP)/carboplatin (C)/ bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC).J. Clin. Oncol. (Meeting Abstracts) 28(15S), 1109 (2010).
60. Sugahara KN, Teesalu T, Karmali PP et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16(6), 510-520 (2009).
61. Sugahara KN, Teesalu T, Karmali PP et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328(5981), 1031-1035 (2010).
62. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10(1), 9-22 (2010).
63. Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad. Sci. USA 106(38), 16157-16162 (2009).
64. Au JLS, Jang SH, Zheng J et al. Determinants of drug delivery and transport to solid tumors. J. Control. Release 74(1-3), 31-46 (2001).
65. Jang SH, Wientjes MG, Au JL. Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. J. Pharmacol. Exp. Ther. 296(3), 1035-1042 (2001).
66. Jang SH, Wientjes MG, Au JL. Determinants of paclitaxel uptake, accumulation and retention in solid tumors. Invest. New Drugs 19(2), 113-123 (2001).
67. Kuh HJ, Jang SH, Wientjes MG, Weaver JR, Au JL. Determinants of paclitaxel penetration and accumulation in human solid tumor. J. Pharmacol. Exp. Ther. 290(2), 871-880 (1999).
68. Zheng JH, Chen CT, Au JL, Wientjes MG. Time- and concentration-dependent penetration of doxorubicin in prostate tumors. AAPS Pharm. Sci. 3(2), E15 (2001).
69. Kuh HJ, Jang SH, Wientjes MG, Au JL. Computational model of intracellular pharmacokinetics of paclitaxel. J. Pharmacol. Exp. Ther. 293(3), 761-770 (2000).
70. Schultz JS, Armstrong W. Permeability of interstitial space of muscle (rat diaphragm) to solutes of different molecular weights. J. Pharm. Sci. 67(5), 696-700 (1978).
71. Au JLS, Li D, Gan Y et al. Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. Cancer Res. 58, 2141-2148 (1998).
72. Au JLS, Kumar RR, Li D, Wientjes MG. Kinetics of hallmark biochemical changes in paclitaxel-induced apoptosis. AAPS Pharm. Sci. 1(3), E8 (1999).
73. Chen CT, Au JL, Wientjes MG. Pharmacodynamics of doxorubicin in human prostate tumors. Clin. Cancer Res. 4(2), 277-282 (1998).
74. Cheng L, Zheng S, Raghunathan K et al. Characterisations of taxolinduced apoptosis and altered gene expression in human breast cancer cells. Cell. Pharmacol. 2, 249-257 (1995).
75. Gan Y, Wientjes MG, Schuller DE, Au JLS. Pharmacodynamics of taxol in human head and neck tumors. Cancer Res. 56, 2086-2093 (1996).
76. Milas L, Hunter NR, Kurdoglu B et al. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother. Pharmacol. 35, 297-303 (1995).
77. Saunders DE, Lawrence WD, Christensen C, Wappler NL, Ruan H, Deppe G. Paclitaxel-induced apoptosis in MCF7 breast cancer cells. Int. J. Cancer 70, 214-220 (1997).
78. Griffon-Etienne G, Boucher Y, Brekken C, Suit Hd, Jain RK. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res. 59, 3776-3782 (1999).
79. Rowinsky EK, Wright M, Monsarrat B, Lesser GJ, Donehower RC. Taxol: pharmacology, metabolism, and clinical applications. Cancer Surv. 283-304 (1993).
80. Rowinsky EK, Donehower RC. Paclitaxel (taxol).N. Engl. J. Med. 332(15), 1004-1014 (1995).
81. Li X, Liu Y, Tang Y, Roger P, Jeng MH, Kao C. Docetaxel increases antitumor efficacy of oncolytic prostate-restricted replicative adenovirus by enhancing cell killing and virus distribution. J. Gene Med. 12(6), 516-527 (2010).
82. Holden SA, Lan Y, Pardo AM, Wesolowski JS, Gillies SD. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents. Clin. Cancer Res. 7(9), 2862-2869 (2001).
83. Spencer CM, Faulds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 48(5), 794-847 (1994).
84. Millenbaugh NJ, Gan Y, Au JLS. Cytostatic and apoptotic effects of paclitaxel in human ovarian tumors. Pharm. Res. 15, 122-127 (1998).
85. Gan Y, Wientjes MG, Lu J, Au JL. Cytostatic and apoptotic effects of paclitaxel in human breast tumors. Cancer Chemother. Pharmacol. 42(3), 177-182 (1998).
86. Chen CT, Gan Y, Au JL, Wientjes MG. Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation. Cancer Res. 58(13), 2777-2783 (1998).
87. Au JLS, Kalns J, Gan Y, Wientjes MG. Pharmacologic effects of taxol in human bladder tumors. Cancer Chemother. Pharmacol. 41, 69-74 (1997).
88. Au JL, Li D, Gan Y et al. Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. Cancer Res. 58(10), 2141-2148 (1998).
89. Yuan F, Dellian M, Fukumura D et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55(17), 3752-3756 (1995).
90. Less JR, Skalak TC, Sevick EM, Jain RK. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res. 51, 265-273 (1991).
91. Lu Z, Tsai M, Lu D, Wang J, Wientjes MG, Au JL. Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer. J. Pharmacol. Exp. Ther. 327(3), 673-682 (2008).
92. Lu Z, Wang J, Wientjes MG, Au JL. Intraperitoneal therapy for peritoneal cancer. Future. Oncol. 6(10), 1625-1641 (2010).
93. Tsai M, Lu Z, Wang J, Yeh TK, Wientjes MG, Au JL. Effects of carrier on disposition and antitumor activity of intraperitoneal Paclitaxel. Pharm. Res 24(9), 1691-1701 (2007).
94. Wong HL, Shen Z, Lu Z, Wientjes MG, Au J. Paclitaxel tumor-priming enhances siRNA delivery and transfection in 3-dimensional tumor cultures. Mol. Pharm. 8(3), 833-840 (2011)
95. Santel A, Aleku M, Keil O et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther. 13(16), 1222-1234 (2006).
96. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5(4), 505-515 (2008).
97. Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm. 5(4), 496-504 (2008).
98. Abe I, Hori K, Saito S, Tanda S, Li YL, Suzuki M. Increased intratumor concentration of fluorescein-isothiocyanatelabeled neocarzinostatin in rats under angiotensin-induced hypertension. Jpn J. Cancer Res. 79, 874-879 (1988).